Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLPAOB)

• Drug Name: Allopurinol Drug Info
• Synonyms: Adenock; Ailural; Ailurial; Allohexal; Allohexan; Alloprin; Allopur; Allopurin; Allopurinolum; Allorin; Allozym; Allpargin; Allural; Aloprim; Alopurinol; Aloral; Alositol; Aluline; Anoprolin; Anzief; Apulonga; Apurin; Apurol; Atisuril; Bleminol; Bloxanth; Caplenal; Capurate; Cellidrin; Cosuric; Dabrosin; Dabroson; Embarin; Epidropal; Epuric; Foligan; Geapur; Gichtex; Gotax; Hamarin; Hexanuret; Jenapurinol; Ketanrift; Ledopur; Lopurin; Lysuron; Milurit; Milurite; Miniplanor; Monarch; Nektrohan; Novopurol; Progout; Pureduct; Purinol; Remid; Riball; Rimapurinol; Roucol; Sigapurol; Suspendol; Takanarumin; Tipuric; Urbol; Uribenz; Uricemil; Uridocid; Uriprim; Uripurinol; Uritas; Urobenyl; Urolit; Urosin; Urtias; Xanthomax; Xanturat; Xanturic; Zygout; Zyloprim; Zyloric; Dura Al; Pan Quimica; A 8003; BW 56158; Urtias 100; AL-100; Allo-Puren; Allohexal (TN); Allopurinol(I); Allosig (TN); Apo-Allopurinol; BW 56-158; Ketobun-A; Progout (TN); Puricos (TN); Quimica, Pan; Zyloprim (TN); Zyloric (TN); BW-56-158; B. W. 56-158; 4-HPP

Indication

Disease Entry	ICD 11	Status	REF
Hyperuricaemia	5C55.Y	Approved	[1] , [2]

• Therapeutic Class: Antimetabolites
• Cross-matching ID:
  PubChem CID: 135401907
  ChEBI ID: CHEBI:40279
  CAS Number: CAS 315-30-0
  TTD Drug ID: DMLPAOB
  VARIDT Drug ID: DR00074
  INTEDE Drug ID: DR0066
  ACDINA Drug ID: D00020

Molecule-Related Drug Atlas

Drug(s) Metabolized By RNA cytidine acetyltransferase (hALP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Folic acid	DMEMBJC	Folate-deficiency anemia	3A02.Y	Approved	[9]
Caffeine	DMKBJWP	Orthostatic hypotension	BA21	Approved	[10]
Procainamide	DMNMXR8	Ventricular arrhythmias	BC71	Approved	[11]
Sulfamethoxazole	DMB08GE	Bacterial infection	1A00-1C4Z	Approved	[12]
Sulfadiazine	DMTW3R8	Rheumatic fever	1B40-1B42	Approved	[13]
Tobramycin	DMUI0CH	Bacterial infection	1A00-1C4Z	Approved	[14]
Mesalazine	DMOL5IU	Ulcerative colitis	DD71	Approved	[15]
Netilmicin	DMRD1QK	Bacterial infection	1A00-1C4Z	Approved	[16]
Clonazepam	DMTO13J	Epilepsy	8A60-8A68	Approved	[17]
Hydralazine	DMU8JGH	Hypertension	BA00-BA04	Approved	[18]

Drug(s) Transported By Organic anion transporter 2 (SLC22A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[19]
Fluorouracil	DMUM7HZ	Solid tumour/cancer	2A00-2F9Z	Approved	[20]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[21]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[22]
Erythromycin	DM4K7GQ	Bacterial infection	1A00-1C4Z	Approved	[23]
Aspirin	DM672AH	Myocardial infarction	BA41-BA43	Approved	[24]
Aciclovir	DMYLOVR	Virus infection	1A24-1D9Z	Approved	[25]
Ranitidine	DM0GUSX	Peptic ulcer	DA61	Approved	[26]
Entecavir	DM7VTQO	Hepatitis B virus infection	1E51.0	Approved	[27]
Theophylline	DMRJFN9	Chronic obstructive pulmonary disease	CA22	Approved	[23]

Drug(s) Transported By Organic anion transporter 3 (SLC22A8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[28]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[21]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[22]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[29]
Pravastatin	DM6A0X7	Hypercholesterolaemia	5C80.0	Approved	[30]
L-tryptophan	DMIBH7M	Depression	6A70-6A7Z	Approved	[31]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[32]
Pitavastatin calcium	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[33]
Rosuvastatin	DMMIQ7G	Hypercholesterolaemia	5C80.0	Approved	[34]
Cilostazol	DMZMSCT	Intermittent claudication	BD40.00	Approved	[35]

Drug(s) Targeting Xanthine dehydrogenase/oxidase (XDH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Febuxostat	DMDEXQ0	Hyperuricaemia	5C55.Y	Approved	[36]
Fosdenopterin	DMR0TYK	Molybdenum cofactor deficiency	5B5K.A	Approved	[37]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[38]
Oxypurinol	DMURH4X	Heart failure	BD10-BD13	Phase 2/3	[39]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[40]
Topiroxostat	DMA04DE	Gout	FA25	Phase 2	[41]
TMX-049	DME8PFQ	Diabetic nephropathy	GB61.Z	Phase 2	[42]
LC-350189	DMHT3CB	Gout	FA25	Phase 1	[43]
Azaindole derivative 5	DMD2BL3	N. A.	N. A.	Patented	[44]
Fused heterocyclic compound 3	DM2QVHY	N. A.	N. A.	Patented	[44]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Xanthine dehydrogenase/oxidase (XDH)	TT7RJY8	XDH_HUMAN	Inhibitor	[3] , [4] , [5]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporter 2 (SLC22A7)	DT0OC1Q	S22A7_HUMAN	Substrate	[6]
Organic anion transporter 3 (SLC22A8)	DTVP67E	S22A8_HUMAN	Substrate	[7]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
RNA cytidine acetyltransferase (hALP) Main DME	DEZV4AP	NAT10_HUMAN	Substrate	[8]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6795).
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018659.
• [3] Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1.
• [4] Purification, crystallization and preliminary X-ray diffraction studies of xanthine dehydrogenase and xanthine oxidase isolated from bovine milk. Acta Crystallogr D Biol Crystallogr. 2000 Dec;56(Pt 12):1656-8.
• [5] Influence of postischemic administration of oxyradical antagonists on ischemic injury to rabbit skeletal muscle. Microsurgery. 1996;17(9):517-23.
• [6] Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14.
• [7] Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83.
• [8] Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. Eur J Clin Pharmacol. 1999 Jan;54(11):869-76.
• [9] Arylamine N-acetyltransferase in human red blood cells. Biochem Pharmacol. 1992 Sep 25;44(6):1099-104.
• [10] A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther. 1993 Aug;54(2):134-41.
• [11] Effect of H2-receptor antagonists on rat liver cytosolic acetyl CoA:arylamine N-acetyltransferase activity. Drug Metab Dispos. 1992 Jan-Feb;20(1):74-8.
• [12] Crystallization and preliminary X-ray characterization of arylamine N-acetyltransferase C (BanatC) from Bacillus anthracis. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Oct 1;63(Pt 10):862-4.
• [13] Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos. 2005 Jul;33(7):969-76.
• [14] Genetic analysis of bacterial acetyltransferases: identification of amino acids determining the specificities of the aminoglycoside 6'-N-acetyltransferase Ib and IIa proteins. J Bacteriol. 1992 May;174(10):3196-203.
• [15] NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis. Z Gastroenterol. 2008 Mar;46(3):259-65.
• [16] Aminoglycoside resistance resulting from tight drug binding to an altered aminoglycoside acetyltransferase. Antimicrob Agents Chemother. 2003 May;47(5):1577-83.
• [17] Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug Metab Lett. 2007 Jan;1(1):3-5.
• [18] Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions, in primary hypertension. Clin Pharmacol Ther. 1981 May;29(5):588-93.
• [19] Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
• [20] Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
• [21] Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
• [22] Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
• [23] Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22.
• [24] Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82.
• [25] Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol. 2008 Apr;73(4):1151-8.
• [26] A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
• [27] Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet. 2017 Feb;32(1):116-119.
• [28] Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74.
• [29] Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
• [30] Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
• [31] Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005 Nov;289(5):C1075-84.
• [32] Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem. 2004 Aug;90(4):931-41.
• [33] Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
• [34] The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
• [35] Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007.
• [36] Clinical pipeline report, company report or official report of Takeda (2009).
• [37] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [38] Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31.
• [39] Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52.
• [40] Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
• [41] QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52.
• [42] Clinical pipeline report, company report or official report of Teijin Pharma.
• [43] Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49.
• [44] An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.